Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on October 8, 2013 (reporting date October 15, 2013). The filing discloses the entry into a Material Definitive Agreement regarding the acquisition of intellectual property rights.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The transaction involves contingent financial obligations rather than immediate cash outflows.
- Acquisition Consideration: Payments are contingent on future milestones, including patent issuance, filing of an Investigational New Drug (IND) application, filing of a New Drug application, and royalty payments based on net receipts.
- Cost Deductions: Royalty calculations allow for the deduction of the Company's development costs associated with the product.
Material Changes
The Company acquired intellectual property related to epinephrine compositions for intraocular administration from Novel Drug Solutions, LLC ("Novel"). This is the second asset acquisition from Novel, executed under a right of first refusal from a prior August 2013 agreement. Additionally, on October 14, 2013, the Company amended the prior August Asset Purchase Agreement to broaden commercialization strategies and adjust termination conditions.
Outlook, Risks, and Contingencies
Management Commentary: The Company is obligated to use commercially reasonable efforts to research, develop, and commercialize a product based on the acquired intellectual property.
Risks and Contingencies:
- Termination Risk: If the Company fails to file an IND or generate royalty payments within five years of the agreement date, Novel may terminate the agreement and demand re-assignment of the technology.
- Amendment Terms: The October 14 amendment to the August agreement similarly allows Novel and Eye Care Northwest, PA to terminate if no study data is derived or royalties are generated within five years.
Investor Verification Checklist
- Verify the status of the provisional patent application for epinephrine compositions.
- Confirm the timeline for filing the first Investigational New Drug (IND) application to avoid termination of the agreement.
- Review the specific royalty rates and net receipt definitions in the Asset Purchase Agreement.
- Assess the Company's current cash position against potential future milestone payments.